Wednesday, October 22, 2025 2:00 PM Eastern Time / 11:00 AM Pacific Time
Presenters:
Dr. Milos Miljkovic – Chief Medical Officer, Cartesian Therapeutics
Descartes-08 is an RNA cell therapy designed to target immune cells which produce autoantibodies directly responsible for symptoms of myasthenia gravis and other autoimmune diseases. In a Phase 2b randomized controlled trial in adults with generalized myasthenia gravis, participants who received Descartes-08 had significant improvement in symptoms compared to placebo, which was maintained through 12 months of follow-up. In this webinar, we will discuss the results of this recently completed trial, as well as the ongoing Phase 3 trial of Descartes-08 in MG (AURORA).
Register
After registering, you will receive a confirmation email containing information about joining the webinar.